CAMP
CAMP4 Therapeutics Corporation NASDAQ Listed Oct 11, 2024$4.34
Mkt Cap $92.2M
52w Low $1.30
47.1% of range
52w High $7.75
50d MA $4.62
200d MA $3.85
P/E (TTM)
-1.5x
EV/EBITDA
-1.6x
P/B
2.6x
Debt/Equity
0.0x
ROE
-168.6%
P/FCF
-6.2x
RSI (14)
—
ATR (14)
—
Beta
0.41
50d MA
$4.62
200d MA
$3.85
Avg Volume
185.4K
CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.
One Kendall Square Bldg 1400 West, 3rd Floor · Cambridge, MA 02139 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | AMC | -0.31 | -0.87 | -180.6% | 4.59 | -2.6% | -8.5% | +49.5% | -3.7% | -7.4% | -3.9% | — |
| Nov 6, 2025 | AMC | -0.47 | -0.55 | -17.0% | 4.45 | -2.2% | -4.5% | -2.1% | -0.7% | +6.3% | -2.7% | — |
| Aug 14, 2025 | AMC | -0.67 | -0.62 | +7.5% | 1.55 | +0.0% | +7.7% | +11.4% | -8.1% | -9.9% | +3.2% | — |
| May 13, 2025 | AMC | -0.70 | -0.62 | +11.4% | 2.02 | +4.0% | -7.9% | +12.9% | +9.5% | -4.8% | +1.8% | — |
| Mar 27, 2025 | AMC | -0.91 | -2.83 | -211.0% | 4.42 | +12.9% | -2.9% | -6.8% | -3.5% | -8.5% | -12.5% | — |
| Oct 11, 2024 | AMC | -1.07 | -0.69 | +35.6% | 10.72 | +4.8% | -9.0% | +10.3% | +1.6% | -0.5% | +1.3% | — |
| Jul 8, 2024 | AMC | -0.92 | -1.61 | -75.0% | — | — | — | — | — | — | — | — |
| Jun 6, 2024 | AMC | -2.04 | -1.03 | +49.7% | — | — | — | — | — | — | — | — |
| Jan 9, 2024 | AMC | -2.30 | -3.91 | -70.0% | — | — | — | — | — | — | — | — |
| Oct 5, 2023 | AMC | -0.00 | -0.01 | -132.9% | — | — | — | — | — | — | — | — |
| Jul 10, 2023 | AMC | 0.92 | -0.23 | -125.0% | — | — | — | — | — | — | — | — |
| Apr 27, 2023 | AMC | 0.23 | 1.38 | +500.0% | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 2 | Leerink Partners | Maintains | Outperform → Outperform | — | $4.46 | $4.39 | -1.6% | +0.2% | +0.4% | +3.6% | -1.5% | -2.0% |
| Sep 16 | JP Morgan | Downgrade | Overweight → Neutral | — | $2.65 | $2.89 | +9.1% | +4.5% | -6.5% | -3.5% | -8.8% | +20.6% |
| Sep 15 | Piper Sandler | Maintains | Overweight → Overweight | — | $3.25 | $3.16 | -2.8% | -18.5% | +4.5% | -6.5% | -3.5% | -8.8% |
| Jan 11 | Goldman Sachs | Maintains | Sell → Sell | — | — | — | — | — | — | — | — | — |
| Oct 9 | Goldman Sachs | Maintains | Sell → Sell | — | — | — | — | — | — | — | — | — |
| Oct 8 | Goldman Sachs | Maintains | Sell → Sell | — | — | — | — | — | — | — | — | — |
| Oct 6 | Roth MKM | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Oct 6 | Craig-Hallum | Downgrade | Buy → Hold | — | — | — | — | — | — | — | — | — |
| Oct 5 | Roth MKM | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Oct 5 | Craig-Hallum | Downgrade | Buy → Hold | — | — | — | — | — | — | — | — | — |
| Aug 29 | Roth MKM | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Aug 28 | Roth MKM | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Jul 13 | Goldman Sachs | Maintains | Sell → Sell | — | — | — | — | — | — | — | — | — |
| Jul 12 | Goldman Sachs | Maintains | Sell → Sell | — | — | — | — | — | — | — | — | — |
| Jul 11 | Craig-Hallum | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Jul 10 | Craig-Hallum | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Jun 26 | Jefferies | Downgrade | Buy → Hold | — | — | — | — | — | — | — | — | — |
| Jun 25 | Jefferies | Downgrade | Buy → Hold | — | — | — | — | — | — | — | — | — |
| May 1 | Goldman Sachs | Maintains | Sell → Sell | — | — | — | — | — | — | — | — | — |
| Apr 30 | Goldman Sachs | Maintains | Sell → Sell | — | — | — | — | — | — | — | — | — |
| Apr 28 | Craig-Hallum | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Apr 27 | Craig-Hallum | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Apr 18 | Goldman Sachs | Maintains | Sell → Sell | — | — | — | — | — | — | — | — | — |
| Apr 17 | Goldman Sachs | Maintains | Sell → Sell | — | — | — | — | — | — | — | — | — |
| Oct 14 | Goldman Sachs | Maintains | Sell → Sell | — | — | — | — | — | — | — | — | — |
| Oct 13 | Goldman Sachs | Maintains | Sell → Sell | — | — | — | — | — | — | — | — | — |
| Aug 16 | Craig-Hallum | Upgrade | Hold → Buy | — | — | — | — | — | — | — | — | — |
| Aug 15 | Craig-Hallum | Upgrade | Hold → Buy | — | — | — | — | — | — | — | — | — |
| Mar 25 | Jefferies | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Mar 24 | Jefferies | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Dec 22 | Canaccord Genuity | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Dec 22 | Craig-Hallum | Downgrade | Buy → Hold | — | — | — | — | — | — | — | — | — |
| Dec 21 | Canaccord Genuity | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Dec 21 | Craig-Hallum | Downgrade | Buy → Hold | — | — | — | — | — | — | — | — | — |
| Jun 25 | Roth Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Jun 24 | Roth Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Apr 23 | Canaccord Genuity | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Apr 22 | Canaccord Genuity | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Mar 18 | Canaccord Genuity | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Mar 17 | Canaccord Genuity | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Dec 18 | JP Morgan | Downgrade | Neutral → Underweight | — | — | — | — | — | — | — | — | — |
| Dec 17 | JP Morgan | Downgrade | Neutral → Underweight | — | — | — | — | — | — | — | — | — |
| Apr 17 | Jefferies | Upgrade | Hold → Buy | — | — | — | — | — | — | — | — | — |
| Apr 16 | Jefferies | Upgrade | Hold → Buy | — | — | — | — | — | — | — | — | — |
| Mar 27 | Goldman Sachs | Maintains | Sell → Sell | — | — | — | — | — | — | — | — | — |
| Mar 19 | Goldman Sachs | Maintains | Sell → Sell | — | — | — | — | — | — | — | — | — |
| Mar 18 | Goldman Sachs | Maintains | Sell → Sell | — | — | — | — | — | — | — | — | — |
| Mar 6 | Canaccord Genuity | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Mar 5 | Canaccord Genuity | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Dec 20 | First Analysis | Downgrade | Outperform → Neutral | — | — | — | — | — | — | — | — | — |
No insider trades available.
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
The appointment of an experienced biotech CFO with Biogen and Big Four audit background strengthens financial credibility, potentially signaling investor confidence and improving governance oversight at CAMP/PTCHF.
Mar 24
8-K · 7.01
! Medium
CAMP4 Therapeutics Corporation -- 8-K 7.01: Regulation FD Disclosure
Camp4 Therapeutics updated its corporate presentation on March 5, 2026, providing investors with refreshed business summaries available on its investor relations website.
Mar 5
Data updated apr 24, 2026 11:46pm
· Source: massive.com